Hung T. Khong, M.D.
Head, Clinical Immunotherapeutics Research Laboratory
and Staff Medical Oncologist
Contact Information:
USA-Mitchell Cancer Institute
1660 Springhill Avenue, Mobile, AL 36607
Telephone: (251) 460-6587
Fax: (251) 460-6994
Email: hkhong@usouthal.edu
Background:
B.A., University of Pennsylvania, 1990
M.D., Temple University School of Medicine, 1994
Resident, Internal Medicine, Baylor College of Medicine, Houston, TX, 1994-1997
Clinical Fellow, Medicine Branch, National Cancer Institute, Bethesda, MD, 1997-2000
Senior Clinical Fellow, Surgery Branch, National Cancer Institute, Bethesda, MD, 2000-2004
University of South Alabama, Mobile, AL, August 2004-Present
Board Certifications :
Internal Medicine, 1999-2009
Medical Oncology, 2000-2010
Research Interests:

Cancer Immunotherapy: To find improved treatments, prevention, and cure for cancers through manipulation of the immune system. There are several major pathways through which we can accomplish our goals: Cancer Vaccines (Lab research), Immune Cell Therapy (Lab research), and Clinical Trials (Clinical research).

Selected Recent Publications :

Khong HT , and Rosenberg SA, Pre-existing immunity to tyrosinase-related protein (TRP)-2, a new TRP-2 isoform, and the NY-ESO-1 melanoma antigen in a patient with a dramatic response to immunotherapy. J. Immunol. 2002. 168:951-956.

Thurber SE, Khong HT , Kammula US, and Rosenberg SA. Identification of endogenous HLA-A2-restricted reactivity against shared melanoma antigens in patients using quantitative real-time PCR. J. Immunother. 2002 25:63-71.

Khong HT , and Rosenberg SA. The Waardenburg syndrome type 4 gene, SOX10, is a novel tumor-associated antigen identified in a patient with a dramatic response to immunotherapy. Cancer Res. 2002. 62(11):3020-3.
Khong HT , and Restifo NP. Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat. Immunol. 2002. 3 (11):999-1005.
Liu G, Khong HT , Wheeler CJ, Black KL, and Ying H. Molecular and functional analysis of tyrosinase related protein (TRP)-2 as a cytotoxic T lymphocyte target in malignant glioma. J. Immunother. 2003. 26:301-312.

Khong HT , Wang QJ, and Rosenberg SA. Identification of multiple antigens recognized by tumor-infiltrating lymphocytes from a single patient: Tumor escape by antigen loss and loss of MHC expression. J. Immunother. 2004. 27(3):184-190.

Khong HT , Yang JC, Topalian SL, Sherry RM, Marincola FM, Mavroukakis SA, White DE, and Rosenberg SA. Immunization of HLA-A*0201 and/or HLA-DPB1*04 Patients with Metastatic Melanoma Using Epitopes from the NY-ESO-1 Antigen. J. Immunother. 2004 Nov-Dec;27(6):472-7.

Klebanoff CA, Khong HT , Antony PA, Palmer DC, and Restifo NP. Sinks, Suppressors, and Antigen Presenter: How Lymphodepletion Can Enhance Adoptive Immunotherapy. Trends Immunol. In Press.

USA Mitchell Cancer Institute

Text Only Options

• Change the current font size: larger | default | smaller
• Current color mode is Black on White, other available modes: Yellow on Black | Black on Cream
• Show textual links as buttons
• Do not move navbars
• Do not alert me when leaving text-mode
• Open not handled documents directly
• Hide Text Only Options

Open the original version of this page.